Mammostrat was a five-marker immunohistochemistry test developed to estimate recurrence risk in early breast cancer, especially estrogen receptor-positive disease treated with endocrine therapy. It combined staining for five proteins—SLC7A5, p53, NDRG1, HTF9C, and CEACAM5—into a prognostic index that classified tumors as low, moderate, or high risk. Unlike newer multigene expression assays, Mammostrat did not sequence genes or measure RNA expression; it used antibody staining on tumor tissue.
The most important current point is that Mammostrat is no longer commercially available. NICE’s updated 2024 guidance on tumor profiling notes that the test became unavailable after earlier guidance had encouraged further research. Current breast cancer guidelines focus instead on validated genomic assays such as Oncotype DX, MammaPrint, Prosigna, EndoPredict, and Breast Cancer Index for specific treatment questions. Mammostrat may still appear in older pathology records, research papers, or historical treatment discussions, so understanding what the categories meant can help place an old result in context.
- Mammostrat was a tissue-based five-protein IHC prognostic test, not a hereditary gene test or blood test.
- Published Mammostrat models classified results as low risk at an index ≤0, moderate risk above 0 through about 0.7, and high risk above 0.7.
- The score was designed mainly to add recurrence-risk information in early, often ER-positive breast cancer receiving endocrine therapy.
- Mammostrat is no longer commercially available, so it is not a current test to order for a new breast cancer diagnosis.
- An old Mammostrat result should be interpreted with stage, lymph nodes, ER, HER2, grade, treatment received, and current evidence rather than used alone to guide modern therapy.
Table of Contents
- What the Mammostrat Test Was
- The Five Mammostrat Biomarkers
- How Low, Moderate, and High Risk Were Classified
- What the Evidence Showed
- Why Mammostrat Is Not Used in Current Practice
- How to Interpret an Old Mammostrat Result
- Current Testing Options and Next Steps
What the Mammostrat Test Was
Mammostrat was an expanded immunohistochemistry assay that turned the staining pattern of five tumor proteins into a breast cancer prognosis score. It was developed before today’s genomic recurrence assays became widely established and was intended to improve risk stratification beyond routine clinical and pathologic features.
The test used formalin-fixed, paraffin-embedded breast tumor tissue, the same general type of material used for standard pathology stains. A laboratory stained the tissue with antibodies against five proteins and recorded each marker as positive or negative under predefined rules. A mathematical algorithm combined those binary results into a prognostic index.
Mammostrat was therefore different from a multigene expression assay. It did not directly measure messenger RNA from dozens of genes and did not produce a gene-expression recurrence score. It was also not a germline test, so it could not determine whether a person carried an inherited BRCA1, BRCA2, PALB2, or other cancer-predisposition variant.
The test was studied most heavily in early-stage breast cancer treated with endocrine therapy, particularly ER-positive postmenopausal populations. Its intended role was prognostic: to estimate the chance of relapse or distant recurrence. Some retrospective analyses also explored whether risk groups might identify patients more likely to benefit from chemotherapy, but that predictive role was less firmly established.
This distinction matters because prognosis and treatment prediction are not the same. A test can identify a group with higher recurrence risk without proving that one specific treatment will reduce that risk by a known amount.
The Five Mammostrat Biomarkers
The Mammostrat panel used SLC7A5, p53, NDRG1, HTF9C, and CEACAM5, five proteins selected because their combined staining pattern was associated with breast cancer outcome. The score did not simply count how many markers were positive; each marker contributed a different weight to the algorithm.
SLC7A5
SLC7A5 is an amino-acid transporter involved in cellular metabolism and growth. In the Mammostrat model, positive SLC7A5 staining carried one of the larger weights in the prognostic index.
p53
p53 is the protein encoded by TP53, a major tumor-suppressor gene. Abnormal p53 protein accumulation on IHC can correlate with TP53 pathway disruption, although IHC is not identical to sequencing the TP53 gene. Mammostrat treated p53 staining as one component of a combined score rather than a stand-alone mutation result.
NDRG1
NDRG1 participates in cell differentiation, stress responses, and cancer biology. Its relationship with prognosis can vary by tumor context, which is one reason Mammostrat relied on a fixed multivariable algorithm rather than interpreting each protein independently.
HTF9C
HTF9C was included as one of the original antibody markers in the assay. It is much less familiar to patients than ER, PR, or HER2 and was not used as an independent standard-of-care breast cancer biomarker outside the Mammostrat model.
CEACAM5
CEACAM5 is a cell-adhesion glycoprotein related to carcinoembryonic antigen biology. As with the other panel proteins, its value in Mammostrat came from the combined pattern rather than from using CEACAM5 alone as a routine breast cancer treatment marker.
These proteins should not be confused with the core breast cancer receptors. The estrogen receptor test, progesterone receptor test, and HER2 testing remain separate diagnostic and predictive tests with direct treatment implications.
How Low, Moderate, and High Risk Were Classified
Published Mammostrat studies converted the five IHC results into a continuous prognostic index and then divided that index into three risk groups. The commonly published thresholds were approximately:
| Mammostrat index | Risk category | General historical interpretation |
|---|---|---|
| ≤0 | Low risk | Lower expected relapse or distant recurrence risk within the studied populations |
| >0 to ≤0.7 | Moderate risk | Intermediate prognostic group |
| >0.7 | High risk | Higher expected recurrence risk within the studied populations |
The underlying published algorithm assigned different coefficients to positive staining for each marker and then subtracted a constant. That means two tumors with the same number of positive markers could still receive different scores if the positive markers were different.
A category such as “low risk” did not mean zero risk. In validation cohorts, recurrences still occurred among low-risk patients. Likewise, “high risk” did not prove that chemotherapy would prevent recurrence. The score needed to be interpreted alongside conventional clinical risk.
It is also important not to translate an old Mammostrat category into the numerical framework of a modern genomic assay. A Mammostrat High Risk result is not equivalent to a high Oncotype DX Recurrence Score, a high MammaPrint category, or a high Prosigna Risk of Recurrence score. Each assay was developed with different biomarkers, populations, statistical models, and treatment evidence.
What the Evidence Showed
Mammostrat showed independent prognostic value in several retrospective analyses, but the evidence base was smaller and less prospective than the evidence supporting the genomic assays used today. Most important studies tested archived tumor samples from patients whose treatment and outcomes were already known.
One validation study examined a large series of women treated with breast-conserving surgery and long-term follow-up. In the main ER-positive group receiving tamoxifen without chemotherapy, Mammostrat separated patients into different recurrence-risk groups even after accounting for standard clinicopathologic factors.
A later analysis used tumor samples from the Tamoxifen Exemestane Adjuvant Multinational, or TEAM, trial. The assay again added prognostic information for distant relapse-free survival in postmenopausal ER-positive disease treated with endocrine therapy. This supported the idea that the five-marker score could identify differing levels of residual risk despite endocrine treatment.
Other work used archived samples from NSABP B-14 and B-20. Those analyses explored both prognosis and chemotherapy interaction. They helped establish the low, moderate, and high score thresholds, but they remained retrospective biomarker analyses rather than a prospective trial in which treatment was assigned by Mammostrat result.
That difference matters. A prospective treatment-decision trial can show whether using a test to choose therapy improves outcomes or safely reduces treatment. Retrospective validation can show that a score correlates with outcome, but it offers less certainty about what should be done because of the score.
By comparison, modern early-stage testing guidance gives specific roles to assays with stronger prospective or prospective-retrospective clinical utility evidence. The 2022 ASCO guideline identifies tests such as Oncotype DX, MammaPrint, EndoPredict, Prosigna, and Breast Cancer Index for particular HR-positive/HER2-negative settings; Mammostrat is not included among the recommended assays.
Why Mammostrat Is Not Used in Current Practice
Mammostrat is not a current ordering option because the commercial test is no longer available, and modern guidelines have moved toward other validated genomic tools. NICE’s 2024 update explicitly notes that Mammostrat is no longer available.
Earlier NICE guidance had reviewed Mammostrat alongside Oncotype DX, MammaPrint, and IHC4 and concluded that additional evidence was needed. Later evidence development was overtaken by stronger validation and wider adoption of other assays. Current international guidance emphasizes genomic tests with clearer clinical utility in defined populations.
Several factors limited Mammostrat’s long-term role:
- the main evidence was retrospective;
- assay availability and commercial support did not persist;
- immunohistochemical scoring can be affected by specimen handling and interpretation;
- the test’s ability to predict chemotherapy benefit was less established than its prognostic association;
- other assays accumulated stronger prospective decision-making evidence;
- modern breast oncology increasingly separates early-stage recurrence assays from metastatic mutation testing and hereditary testing.
This does not mean the original Mammostrat research was invalid. It means the clinical ecosystem changed. A biomarker test needs not only biologic plausibility and retrospective validation but also reproducibility, available laboratory infrastructure, regulatory and commercial continuity, guideline support, and evidence that the result changes care in a beneficial way.
Why an IHC panel can differ from a genomic assay
Immunohistochemistry has practical advantages. It can be performed on standard pathology material, uses techniques familiar to most pathology laboratories, and can be less technically complex than RNA-expression profiling. But an expanded IHC panel also inherits the variability of antibody staining and visual interpretation. Fixation, antibody performance, staining thresholds, tumor heterogeneity, and reader interpretation can change whether a marker is called positive or negative. Because the original Mammostrat algorithm converted each marker to a binary value, a borderline stain could affect the final category more than a patient might expect.
Modern genomic assays also have technical limitations, but many use centralized or tightly standardized platforms and have been validated in large treatment-decision studies. Their clinical role is not simply a consequence of measuring genes rather than proteins; it comes from the evidence connecting a particular assay result to a particular clinical decision.
That is why an old Mammostrat result cannot be recreated by looking at routine p53 or CEACAM5 staining today. The commercial assay depended on a defined set of antibodies, scoring rules, and a prespecified algorithm. A pathologist cannot reliably infer the original low, moderate, or high category from a few standard stains performed for another purpose.
How to Interpret an Old Mammostrat Result
An old Mammostrat report can still provide historical prognostic context, but it should not be used by itself to make a new treatment decision years later. The first step is to identify exactly when and why the test was ordered.
Review the original report for:
- the numerical prognostic index, if provided;
- the low, moderate, or high risk category;
- ER, PR, and HER2 status at the time;
- tumor size and histologic grade;
- lymph-node involvement;
- whether chemotherapy was given;
- which endocrine therapy was used and for how long;
- whether the patient has remained recurrence-free or has developed recurrent disease.
A person who had a Low Risk result 12 years ago and remains disease-free has already accumulated years of real-world outcome information that may matter more than recalculating the historical score. Conversely, if cancer has recurred or become metastatic, current tumor biology becomes the priority. Modern treatment selection may require a new biopsy, repeat ER/HER2 testing, and molecular testing for actionable alterations rather than relying on the original Mammostrat category.
If an old report says “moderate risk,” do not assume a modern genomic test would produce an intermediate result. The assays are not calibrated to each other. Re-testing archived tissue with a currently validated assay may be considered only if the result would still answer a relevant clinical question and the assay is validated for that situation.
Current Testing Options and Next Steps
For a new HR-positive/HER2-negative early breast cancer diagnosis, clinicians now choose among current genomic assays based on age, menopausal status, nodal involvement, and the treatment question rather than ordering Mammostrat. The test that fits best depends on what needs to be decided.
For chemotherapy decisions, Oncotype DX and MammaPrint have major prospective evidence in defined populations. Prosigna PAM50 and EndoPredict can provide prognostic information in selected postmenopausal HR-positive/HER2-negative early-stage cancers. Breast Cancer Index may be useful for some questions about late recurrence and extended endocrine therapy.
The choice should begin with a clear question:
- Is chemotherapy benefit uncertain after standard clinical-pathologic assessment?
- Is the patient premenopausal or postmenopausal?
- Are lymph nodes negative, or are one to three nodes involved?
- Is the tumor ER-positive and HER2-negative?
- Is the question about early recurrence, late recurrence, extended endocrine therapy, or metastatic treatment?
- Will the result actually change the treatment recommendation?
A test should not be ordered simply because it is available. Modern biomarker practice works best when each assay is matched to the decision it has been validated to inform.
For someone reviewing an old Mammostrat result, the most useful next step is usually not to search for the discontinued test. Bring the report to a breast oncologist, confirm the current disease status, and ask whether any modern pathology or genomic testing would change management today.
If the report lists only a category such as Low, Moderate, or High Risk, that category should be interpreted in the context of the assay version and the patient population in which Mammostrat was studied. It should not be converted into a modern recurrence-score percentage or mapped directly onto a current genomic assay. Different tests measure different biology, use different algorithms, and were validated for different treatment decisions. A new assay result, when appropriate, must be interpreted on its own terms rather than treated as an updated Mammostrat score.
If the original cancer was treated many years ago, also ask whether the current question is about the original recurrence risk or about a new clinical problem. A historical prognosis test cannot diagnose a new breast mass, determine whether a new lesion is a recurrence, or choose therapy for metastatic disease. Those questions require current imaging, pathology, receptor testing, and, when indicated, contemporary molecular testing.
For historical records, keeping the original pathology report is especially useful. The antibody results, risk category, specimen date, and treatment context may help an oncologist understand what the old test meant, even when the commercial assay is no longer part of current practice. A copied risk label without those details is much harder to interpret and should not be used to reconstruct a modern treatment recommendation.
References
- Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer 2024 (Guideline)
- Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update 2022 (Guideline)
- Biomarkers in breast cancer 2024: an updated consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology 2024 (Position Statement)
- Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy 2010
- Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study 2012
- Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials 2008
Disclaimer
This article is for general education and historical interpretation and does not replace advice from a breast oncology team. Mammostrat is no longer commercially available, and an old risk category should not be used alone to start, stop, or change current cancer treatment. Modern testing should be selected according to the present disease setting and current clinical guidelines.
